{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:08:00Z","timestamp":1793502480342,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.aohep.2025.101900","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:17:18Z","timestamp":1741900638000},"page":"101900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases"],"prefix":"10.1016","volume":"30","author":[{"given":"Patrizia","family":"Burra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-1998","authenticated-orcid":false,"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2025.101900_bib0001","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.3350\/cmh.2022.0348","article-title":"Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future","volume":"29","author":"Reinson","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0002","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","author":"Loaeza-del-Castillo","year":"2008","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0003","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1665-2681(19)31345-6","article-title":"Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study","volume":"12","author":"Yap","year":"2013","journal-title":"Ann Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.101900_bib0006","first-page":"817","article-title":"The past and present of serum aminotransferases and the future of live r injury biomarkers","volume":"15","author":"McGill","year":"2016","journal-title":"EXCLI J"},{"issue":"24","key":"10.1016\/j.aohep.2025.101900_bib0007","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3748\/wjg.v30.i24.3016","article-title":"Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: long life to the old biomarker!","volume":"30","author":"Lonardo","year":"2024","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0008","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0009","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"(EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101900_bib0011","doi-asserted-by":"crossref","DOI":"10.21037\/tgh.2020.04.04","article-title":"Undiagnosed liver diseases","volume":"6","author":"Gao","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0012","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7150\/ijms.8951","article-title":"Alanine aminotransferase-old biomarker and new concept: a review","volume":"11","author":"Liu","year":"2014","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0013","first-page":"1","article-title":"Environment-wide association study of elevated liver enzymes: results from the Korean National Environmental Health Survey 2018 2022","volume":"35","author":"Chi","year":"2023","journal-title":"Ann Occup Environ Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.aohep.2025.101900_bib0015","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for Alanine aminotransferase levels: a 20 21 update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2025.101900_bib0016","series-title":"Schiff's diseases of the liver","first-page":"17","article-title":"Laboratory tests","author":"Herlong","year":"2011"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0017","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1590-8658(03)00378-5","article-title":"Body mass index is a good predictor of an elevated alanine transaminas e level in the general population: hints from the Dionysos study","volume":"35","author":"Bedogni","year":"2003","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.aohep.2025.101900_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1695874","article-title":"Alanine aminotransferase and body composition in obese men and women","volume":"2019","author":"Bekkelund","year":"2019","journal-title":"Dis. Markers"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0019","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s40200-022-01137-6","article-title":"Is elevated ALT associated with lifestyle risk factors? A population-b ased survey","volume":"21","author":"Balali","year":"2022","journal-title":"J Diab Metab Disord"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00592-023-02209-6","article-title":"Alanine transferase levels (ALT) and triglyceride-glucose index are ri sk factors for type 2 diabetes mellitus in obese patients","volume":"61","author":"Folli","year":"2024","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0021","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.arcmed.2012.08.005","article-title":"Population-based risk factors for elevated alanine aminotransferase in a south Texas Mexican\u2013American Population","volume":"43","author":"Qu","year":"2012","journal-title":"Arch. Med. Res."},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgast-2022-000870","article-title":"Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population","volume":"9","author":"Huong","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0023","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.24356","article-title":"Elevated AST\/ALT ratio is associated with all-cause mortality and canc er incident","volume":"36","author":"Chen","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0025","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cam4.4473","article-title":"Aspartate aminotransferase\/alanine aminotransferase ratio and subseque nt cancer development","volume":"11","author":"Kobayashi","year":"2022","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0026","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/hep4.1700","article-title":"A dynamic aspartate-to-alanine aminotransferase ratio provides valid P redictions of incident severe liver disease","volume":"5","author":"\u00c5berg","year":"2021","journal-title":"Hepatol Communs"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0027","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/hep4.1844","article-title":"Oh TK. Validation of dynamic aspartate-to\u2013Alanine aminotransferase ratio for predicting liver disease mortality","volume":"6","author":"Song","year":"2022","journal-title":"Hepatol Communs"},{"issue":"11","key":"10.1016\/j.aohep.2025.101900_bib0028","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","article-title":"Abnormal liver enzymes: a review for clinicians","volume":"13","author":"Kalas","year":"2021","journal-title":"World J Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2025.101900_bib0029","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systemat ic review and meta-analysis","volume":"7","author":"Im","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cld.2018.06.002","article-title":"Hepatitis B and C","volume":"22","author":"Mysore","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0031","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1572-0241.2008.01825.x","article-title":"Acute hepatitis C: a systematic review","volume":"103","author":"Kamal","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.101900_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107115","article-title":"A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort","volume":"146","author":"Kondili","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0033","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0034","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000103901","article-title":"Hepatitis C virus with normal transaminase levels","volume":"25","author":"Puoti","year":"2007","journal-title":"Digestive Diseases"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/ejim.ejim_24_19","article-title":"Prevalence and effect of occult hepatitis C infection in patients with persistent liver enzyme elevation after achieving 24 weeks of sustain ed virological response","volume":"31","author":"Mohamed","year":"2019","journal-title":"Egypt J Intern Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/v15010183","article-title":"Chronic Hepatitis C: acute exacerbation and alanine aminotransferase F lare","volume":"15","author":"Kanda","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0037","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MEG.0000000000002708","article-title":"AST to ALT ratio as a prospective risk predictor for liver cirrhosis i n patients with chronic HBV infection","volume":"36","author":"Lai","year":"2024","journal-title":"Europ J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/bjsopen\/zrad155","article-title":"Prognostic value of aspartate aminotransferase\/alanine aminotransferas e ratio in hepatocellular carcinoma after hepatectomy","volume":"8","author":"Huo","year":"2024","journal-title":"BJS Open"},{"key":"10.1016\/j.aohep.2025.101900_bib0039","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0040","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"Metabolic dysfunction\u2013associated fatty liver disease (MAFLD): an updat e of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J. Physiol. Biochem."},{"issue":"8","key":"10.1016\/j.aohep.2025.101900_bib0041","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1631\/jzus.B0720016","article-title":"Relationship between alanine aminotransferase levels and metabolic syn drome in nonalcoholic fatty liver disease","volume":"9","author":"Chen","year":"2008","journal-title":"J Zhejiang Univer: Sci B"},{"issue":"8","key":"10.1016\/j.aohep.2025.101900_bib0042","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.nutres.2012.06.019","article-title":"The lipid accumulation product is highly related to serum alanine amin otransferase level in male adults","volume":"32","author":"Ji","year":"2012","journal-title":"Nutr Res"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0043","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jfma.2011.04.004","article-title":"Impact of increasing alanine aminotransferase levels within normal ran ge on incident diabetes","volume":"111","author":"Wang","year":"2012","journal-title":"J Formosan Med Assoc"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0044","first-page":"e573","article-title":"Visceral adipose tissue area as an independent risk factor for elevate d liver enzyme in nonalcoholic fatty liver disease","volume":"94","author":"Chung","year":"2015","journal-title":"Medicine (United States)"},{"issue":"10","key":"10.1016\/j.aohep.2025.101900_bib0045","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3748\/wjg.v30.i10.1346","article-title":"Cumulative effects of excess high-normal alanine aminotransferase leve ls in relation to new-onset metabolic dysfunction-associated fatty liv er disease in China","volume":"30","author":"Chen","year":"2024","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101280","article-title":"Optimal ALT threshold for the automated diagnosis of MASLD: a populati on-based study using iLFT","volume":"29","author":"Lee","year":"2024","journal-title":"Ann Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0047","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.101900_bib0048","article-title":"Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States","volume":"15","author":"Xuan","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0049","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MCG.0b013e31818980ac","article-title":"Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis","volume":"43","author":"Su","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0050","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/j.1572-0241.2007.01274.x","article-title":"Light to moderate alcohol consumption is associated with lower frequen cy of hypertransaminasemia","volume":"102","author":"Suzuki","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.aohep.2025.101900_bib0051","article-title":"Clinical presentation of alcoholic liver disease and non-alcoholic fat ty liver disease: spectrum and diagnosis","volume":"5","author":"Sharma","year":"2020","journal-title":"Transl Gastroenterold Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-021-02215-x","article-title":"Modest alcohol intake and mortality in individuals with elevated alani ne aminotransferase levels: a nationwide cohort study","volume":"20","author":"Sinn","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0053","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 pra ctice guidance from the American Association for the Study of liver di seases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0054","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following Drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0055","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000149","article-title":"Association of the etiology and peak level of markedly elevated aminot ransferases with mortality: a multicenter study","volume":"7","author":"Kwak","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0056","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0057","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk asses sment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0058","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0059","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jama.296.1.87","article-title":"Aminotransferase elevations in healthy adults receiving 4 grams of ace taminophen daily: a randomized controlled trial","volume":"296","author":"Watkins","year":"2006","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.aohep.2025.101900_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4254\/wjh.v9.i10.491","article-title":"Drug-induced liver injury: do we know everything?","volume":"9","author":"Alempijevic","year":"2017","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0061","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"issue":"June","key":"10.1016\/j.aohep.2025.101900_bib0062","first-page":"1","article-title":"Challenges in herbal-induced liver injury identification and preventio n","author":"Halegoua-DeMarzio","year":"2024","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0063","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0064","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/hep.31157","article-title":"Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes","volume":"72","author":"Natarajan","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101900_bib0066","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2012.11.002","article-title":"Autoimmune hepatitis: a comprehensive review","volume":"41","author":"Liberal","year":"2013","journal-title":"J. Autoimmun."},{"issue":"August 2023","key":"10.1016\/j.aohep.2025.101900_bib0067","article-title":"Liver inflammation activity in patients with autoimmune hepatitis with normal alanine aminotransferase and immunoglobulin G levels","volume":"8","author":"Chen","year":"2024","journal-title":"J Transl Autoimmun"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0068","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/liv.14082","article-title":"Long-term clinical outcomes in patients with autoimmune hepatitis acco rding to treatment response in Asian country","volume":"39","author":"Choi","year":"2019","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.aohep.2025.101900_bib0069","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.cgh.2021.05.024","article-title":"Aminotransferases during treatment predict long-term survival in patie nts with Autoimmune Hepatitis type 1: a landmark analysis","volume":"20","author":"Biewenga","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0070","article-title":"Link between persistent, unexplained gamma-glutamyltransferase elevation and porto-sinusoidal vascular disorder","volume":"6","author":"Pugliese","year":"2024","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0071","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"Gottardi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0072","article-title":"Alanine aminotransferase elevation in obese infants and children: a ma rker of early onset non alcoholic fatty liver disease","volume":"14","author":"Engelmann","year":"2014","journal-title":"Hepat Mon"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0073","first-page":"1","article-title":"Prevalence and risk factors of elevated alanine aminotransferase among Korean adolescents: 2001-2014","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Public Heal"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0074","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00431-023-04825-4","article-title":"Incidental hypertransaminasemia in children\u2014A stepwise approach in pri mary care","volume":"182","author":"Costa","year":"2023","journal-title":"Eur. J. Pediatr."},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0075","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1053\/j.gastro.2009.12.052","article-title":"SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease","volume":"138","author":"Schwimmer","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0076","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29542","article-title":"New pediatric percentiles of liver enzyme serum levels (alanine aminot ransferase, aspartate aminotransferase, \u03b3-glutamyltransferase): effect s of age, sex, body mass index, and pubertal stage","volume":"68","author":"Bussler","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.101900_bib0077","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4240380","article-title":"Prevalence of elevated Alanine aminotransferase by diagnostic criterio n, age, and gender among adolescents","volume":"2020","author":"Zhang","year":"2020","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0078","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MPG.0b013e31818fc63b","article-title":"Age- and sex-related reference ranges of alanine aminotransferase leve ls in children: european paediatric HCV network","volume":"49","author":"England","year":"2009","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"18","key":"10.1016\/j.aohep.2025.101900_bib0079","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3748\/wjg.v19.i18.2740","article-title":"Persistent hypertransaminasemia in asymptomatic children: a stepwise a pproach","volume":"19","author":"Vajro","year":"2013","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0080","first-page":"E441","article-title":"Liver diseases in pregnancy","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Med, J Royal College Phys London."},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0081","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13091388","article-title":"Diagnostic approach to elevated liver function tests during pregnancy: a pragmatic narrative review","volume":"13","author":"Dajti","year":"2023","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0082","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2023.03.006","article-title":"EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy","volume":"79","author":"Williamson","year":"2023","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.aohep.2025.101900_bib0083","first-page":"322","article-title":"A systematic approach to pregnancy-specific liver disorders","volume":"17","author":"Verma","year":"2021","journal-title":"Gastroenterol Hepatol (Que)"},{"key":"10.1016\/j.aohep.2025.101900_bib0084","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.12659\/MSM.907723","article-title":"Liver disease during pregnancy: a challenging clinical issue","volume":"24","author":"Mikolasevic","year":"2018","journal-title":"Med Sci Monit"},{"issue":"18","key":"10.1016\/j.aohep.2025.101900_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21180","article-title":"Development and validation of prediction models for risks of complicat ions in early-onset pre-eclampsia (PREP): a prospective cohort study","volume":"21","author":"Thangaratinam","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.aohep.2025.101900_bib0086","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2018.01.004","article-title":"Temporal and external validation of the fullPIERS model for the predic tion of adverse maternal outcomes in women with pre-eclampsia","volume":"15","author":"Ukah","year":"2019","journal-title":"Pregnancy Hypertens"},{"issue":"January","key":"10.1016\/j.aohep.2025.101900_bib0087","article-title":"The interpretation of liver function tests in pregnancy","volume":"44-45","author":"Guarino","year":"2020","journal-title":"Best Practice and Res: Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0088","doi-asserted-by":"crossref","first-page":"271","DOI":"10.6061\/clinics\/2014(04)09","article-title":"Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review","volume":"69","author":"Cavalcanti Sette","year":"2014","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0089","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jh367w","article-title":"Alterations of hematological parameters, hemoglobin and hematocrit wit h liver enzymes, aspartate transaminase and alanine transaminase among patients with chronic kidney disease undergoing hemodialysis in Aljou f Region, Saudi Arabia","volume":"7","author":"Khan","year":"2018","journal-title":"J Hematol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0090","first-page":"13","article-title":"The effects of chronic kidney disease on liver function tests: the lab oratory interpretation perspective","volume":"10","author":"Gatua","year":"2019","journal-title":"Asian J Med Sci"},{"issue":"July","key":"10.1016\/j.aohep.2025.101900_bib0091","article-title":"Evaluation of liver function biomarkers, blood pressure, and anthropom etric parameters among chronic kidney disease patients: laboratory-bas ed cross-sectional study in Northwest Ethiopia","volume":"19","author":"Agidew","year":"2023","journal-title":"Metabol Open"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0092","doi-asserted-by":"crossref","first-page":"346","DOI":"10.6061\/clinics\/2015(05)07","article-title":"The reduction of serum aminotransferase levels is proportional to the decline of the glomerular filtration rate in patients with chronic kid ney disease","volume":"70","author":"Sette","year":"2015","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-020-01840-7","article-title":"Association between aminotransferase\/alanine aminotransferase ratio an d cardiovascular disease mortality in patients on peritoneal dialysis: a multi-center retrospective study","volume":"21","author":"Feng","year":"2020","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0094","doi-asserted-by":"crossref","first-page":"428","DOI":"10.14218\/JCTH.2023.00446","article-title":"Subnormal serum liver enzyme levels: a review of pathophysiology and clinical significance","volume":"12","author":"Youssef","year":"2024","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0095","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/ajkd.2001.28590","article-title":"Decreased serum aminotransferase activity in patients with chronic ren al failure: impact on the detection of viral hepatitis","volume":"38","author":"Fabrizi","year":"2001","journal-title":"Am J kidney diseases"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0096","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/2229-516X.149232","article-title":"A comparative study of serum aminotransferases in chronic kidney disea se with and without end-stage renal disease: need for new reference ra nges","volume":"5","author":"Ray","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0097","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.transproceed.2022.02.045","article-title":"Early postoperative transaminase activities affecting Early and late L iver graft survival","volume":"54","author":"Figiel","year":"2022","journal-title":"Transplant. Proc."},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0098","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CLD.0000000000000057","article-title":"Evaluation and management of abnormal liver enzymes in the liver trans plant recipient: when, why, and what now?","volume":"21","author":"Harding-Theobald","year":"2023","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"S1","key":"10.1016\/j.aohep.2025.101900_bib0099","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/j.jhep.2015.02.042","article-title":"From immunosuppression to tolerance","volume":"62","author":"Adams","year":"2015","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.aohep.2025.101900_bib0100","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.transproceed.2019.04.062","article-title":"Range of normal serum aminotransferase levels in liver transplant reci pients","volume":"51","author":"Siddiqui","year":"2019","journal-title":"Transplant. Proc."},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-020-1165-z","article-title":"Proportion of NAFLD patients with normal ALT value in overall NAFLD pa tients: a systematic review and meta-analysis","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"1086","key":"10.1016\/j.aohep.2025.101900_bib0102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/postgradmedj-2015-133715","article-title":"Evaluation of abnormal liver function tests","volume":"92","author":"Agrawal","year":"2016","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.aohep.2025.101900_bib0103","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver an d cardiovascular events, and all-cause mortality in individuals with o besity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Regional Heal - Europe"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-62549-3","article-title":"Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease","volume":"14","author":"Ouzan","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of pati ents with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101900_bib0106","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1080\/00365521.2022.2094725","article-title":"Only one-third of referrals for fatty liver disease are on time: real- world study reveals opportunities to avoid unnecessary and delayed ref errals","volume":"57","author":"Lindvig","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"issue":"20","key":"10.1016\/j.aohep.2025.101900_bib0107","first-page":"1","article-title":"Care for vulnerable populations with chronic liver disease: a safety-N et perspective","volume":"11","author":"Wang","year":"2023","journal-title":"Healthcare (Switzerland)"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-022-04163-1","article-title":"Critical care hepatology: definitions, incidence, prognosis and role o f liver failure in critically ill patients","volume":"26","author":"Perez Ruiz de Garibay","year":"2022","journal-title":"Critic Care"},{"issue":"725","key":"10.1016\/j.aohep.2025.101900_bib0109","doi-asserted-by":"crossref","first-page":"E916","DOI":"10.3399\/BJGP.2022.0094","article-title":"Liver disease management as routine work in primary care: a qualitativ e interview study to guide implementation","volume":"72","author":"Jarvis","year":"2022","journal-title":"British J General Prac"},{"issue":"March","key":"10.1016\/j.aohep.2025.101900_bib0110","article-title":"Development and implementation of a continuing medical education progr am on non-alcoholic fatty liver disease for primary care practitioners in Europe","volume":"10","author":"Papadakis","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101848","article-title":"Awareness of chronic liver diseases, a comparison between diabetologis ts and general practitioners","volume":"46","author":"Canivet","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101900_bib0112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2023.04.022","article-title":"The future of hepatology \u2013 \u201cThe best way to predict the future is to c reate it","volume":"79","author":"Berg","year":"2023","journal-title":"J. Hepatol."},{"issue":"January","key":"10.1016\/j.aohep.2025.101900_bib0113","first-page":"1","article-title":"Health technology adoption in liver disease: innovative use of data Sc ience solutions for early disease detection","volume":"4","author":"Bennett","year":"2022","journal-title":"Front Digital Heal"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0114","doi-asserted-by":"crossref","first-page":"E0035","DOI":"10.1097\/HC9.0000000000000035","article-title":"Clinical decision support automates care gap detection among primary c are patients with nonalcoholic fatty liver disease","volume":"7","author":"Spann","year":"2023","journal-title":"Hepatol Commun"},{"issue":"8 August","key":"10.1016\/j.aohep.2025.101900_bib0115","first-page":"1","article-title":"Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning","volume":"16","author":"Guo","year":"2021","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MCG.0000000000001586","article-title":"An AI approach for identifying patients with cirrhosis","volume":"57","author":"Obeid","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"issue":"7","key":"10.1016\/j.aohep.2025.101900_bib0117","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s10620-024-08437-2","article-title":"An electronic health record model for predicting risk of hepatic fibro sis in primary care patients","volume":"69","author":"Thrift","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.aohep.2025.101900_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2023.107932","article-title":"Application of artificial intelligence techniques for non-alcoholic fa tty liver disease diagnosis: a systematic review (2005\u20132023)","volume":"244","author":"Zamanian","year":"2024","journal-title":"Comput Method Programs Biomed"},{"issue":"March","key":"10.1016\/j.aohep.2025.101900_bib0119","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijmedinf.2019.06.028","article-title":"Augmented intelligence with natural language processing applied to ele ctronic health records for identifying patients with non-alcoholic fat ty liver disease at risk for disease progression","volume":"129","author":"Vleck","year":"2019","journal-title":"Int J Med Inform"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100443","article-title":"Artificial intelligence in liver diseases: improving diagnostics, prog nostics and response prediction","volume":"4","author":"Nam","year":"2022","journal-title":"JHEP Reports"},{"issue":"11","key":"10.1016\/j.aohep.2025.101900_bib0121","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.dld.2023.08.048","article-title":"Artificial intelligence and liver: opportunities and barriers","volume":"55","author":"Balsano","year":"2023","journal-title":"Diges Liver Disease"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0122","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000575","article-title":"Digital Therapeutics: emerging new therapy for nonalcoholic fatty live r disease","volume":"14","author":"Zhou","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101900_bib0123","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jgh3.13021","article-title":"Integrating smart phone applications in the management of cirrhotic pa tients: a scoping review","volume":"7","author":"Hasan","year":"2023","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0124","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000429","article-title":"The rise of mobile apps for the management of chronic liver disease","volume":"8","author":"Ozturk","year":"2024","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.aohep.2025.101900_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100993","article-title":"AlcoChange: a digital therapeutic for patients with alcohol-related li ver disease","volume":"6","author":"Mehta","year":"2024","journal-title":"JHEP Reports"},{"issue":"10319","key":"10.1016\/j.aohep.2025.101900_bib0126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL\u2013Lancet Liver Commission: protecting the next generation of Eu ropeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"The Lancet"},{"issue":"9","key":"10.1016\/j.aohep.2025.101900_bib0127","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/imj.14986","article-title":"Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis","volume":"50","author":"Hayward","year":"2020","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12912-023-01580-7","article-title":"Knowledge needs in patients with Liver Disease: a qualitative study","volume":"22","author":"Jacobsen","year":"2023","journal-title":"BMC Nurs"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101750","article-title":"Liver health literacy and social stigma of liver disease: a general po pulation e-survey","volume":"45","author":"Wahlin","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10436","key":"10.1016\/j.aohep.2025.101900_bib0130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(24)00204-6","article-title":"The EASL\u2013Lancet Commission on liver health in Europe: prevention, case -finding, and early diagnosis to reduce liver-related mortality","volume":"403","author":"Karlsen","year":"2024","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.aohep.2025.101900_bib0131","doi-asserted-by":"crossref","first-page":"207","DOI":"10.14740\/jocmr2914w","article-title":"The effectiveness of a liver disease education class for providing inf ormation to patients and their families","volume":"9","author":"Kadokawa","year":"2017","journal-title":"J Clin Med Res"},{"issue":"5","key":"10.1016\/j.aohep.2025.101900_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Reports"},{"key":"10.1016\/j.aohep.2025.101900_bib0133","unstructured":"Uptodate.com. Patient education: cirrhosis (Beyond the Basics). Available at: https:\/\/www.uptodate.com\/contents\/cirrhosis-beyond-the-basics."},{"issue":"11","key":"10.1016\/j.aohep.2025.101900_bib0134","first-page":"709","article-title":"Mildly elevated liver transaminase levels: causes and evaluation","volume":"96","author":"Oh","year":"2017","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.aohep.2025.101900_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2013.09.005","article-title":"Evaluation of abnormal liver tests","volume":"98","author":"Woreta","year":"2014","journal-title":"Med Clinic North Am"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:34:15Z","timestamp":1777782855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1665268125001243"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101900","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101900"}}